Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been recommended for the treatment of patients with type 2 diabetes mellitus and cardiovascular disease, heart failure or chronic kidney disease. Findings from recent efficacy and safety trials of empagliflozin in kidney transplant recipients with post-transplantation diabetes are timely, given the elevated cardiovascular risk associated with solid organ transplantation.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jenssen, T. & Hartmann, A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat. Rev. Endocrinol. 15, 172–188 (2019).
DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).
Schwaiger, E. et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am. J. Transplant. 19, 907–919 (2019).
Halden, T. A. S. et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 42, 1067–1074 (2019).
Handelsman, Y. et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of Sglt-2 inhibitors and diabetic ketoacidosis. Endocr. Pract. 22, 753–762 (2016).
Davies, M. J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61, 2461–2498 (2018).
The Empa-Renal Tx study from Oslo, Norway, was initiated and funded by the investigators and supported by grants from the South-Eastern Norway Regional Health Authority, the Norwegian Diabetes Association and Oslo Diabetes Research Centre. This study was supported by an unrestricted grant from Boehringer Ingelheim, Norway.
T.J. has received lecture honoraria from Boehringer Ingelheim, AstraZeneca and Merck Sharp & Dohme. M.H. declares no competing interests.
About this article
Cite this article
Hecking, M., Jenssen, T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nat Rev Nephrol 15, 525–526 (2019). https://doi.org/10.1038/s41581-019-0173-0
Cardiovascular events associate with diabetes status rather than with early basal insulin treatment for the prevention of post-transplantation diabetes mellitus
Nephrology Dialysis Transplantation (2019)